Mogamulizumab forecast: Clearer patients, with a slight chance of immune mayhem

Cecilia Larocca; Thomas S. Kupper; Nicole R. LeBoeuf

doi:10.1158/1078-0432.CCR-19-2742

Mogamulizumab forecast: Clearer patients, with a slight chance of immune mayhem

Cecilia Larocca
, Thomas S. Kupper
, Nicole R. LeBoeuf

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Mogamulizumab, approved by the FDA for relapsed or refractory mycosis fungoides and Sézary syndrome, improves progression-free survival compared with vorinostat in the largest trial to date in cutaneous T-cell lymphoma, with particular efficacy in leukemic disease, but carries a risk of immune-mediated toxicities with concomitant depletion of regulatory T cells.

Original language	English (US)
Pages (from-to)	7272-7274
Number of pages	3
Journal	Clinical Cancer Research
Volume	25
Issue number	24
DOIs	https://doi.org/10.1158/1078-0432.CCR-19-2742
State	Published - Dec 15 2019
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-19-2742

Cite this

@article{c2c6b8487cff4c7e81e8dcb2f56e9418,

title = "Mogamulizumab forecast: Clearer patients, with a slight chance of immune mayhem",

abstract = "Mogamulizumab, approved by the FDA for relapsed or refractory mycosis fungoides and S{\'e}zary syndrome, improves progression-free survival compared with vorinostat in the largest trial to date in cutaneous T-cell lymphoma, with particular efficacy in leukemic disease, but carries a risk of immune-mediated toxicities with concomitant depletion of regulatory T cells.",

author = "Cecilia Larocca and Kupper, \{Thomas S.\} and LeBoeuf, \{Nicole R.\}",

note = "Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",

year = "2019",

month = dec,

day = "15",

doi = "10.1158/1078-0432.CCR-19-2742",

language = "English (US)",

volume = "25",

pages = "7272--7274",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "24",

}

TY - JOUR

T1 - Mogamulizumab forecast

T2 - Clearer patients, with a slight chance of immune mayhem

AU - Larocca, Cecilia

AU - Kupper, Thomas S.

AU - LeBoeuf, Nicole R.

PY - 2019/12/15

Y1 - 2019/12/15

N2 - Mogamulizumab, approved by the FDA for relapsed or refractory mycosis fungoides and Sézary syndrome, improves progression-free survival compared with vorinostat in the largest trial to date in cutaneous T-cell lymphoma, with particular efficacy in leukemic disease, but carries a risk of immune-mediated toxicities with concomitant depletion of regulatory T cells.

AB - Mogamulizumab, approved by the FDA for relapsed or refractory mycosis fungoides and Sézary syndrome, improves progression-free survival compared with vorinostat in the largest trial to date in cutaneous T-cell lymphoma, with particular efficacy in leukemic disease, but carries a risk of immune-mediated toxicities with concomitant depletion of regulatory T cells.

UR - https://www.scopus.com/pages/publications/85076503737

UR - https://www.scopus.com/pages/publications/85076503737#tab=citedBy

U2 - 10.1158/1078-0432.CCR-19-2742

DO - 10.1158/1078-0432.CCR-19-2742

M3 - Article

C2 - 31615932

AN - SCOPUS:85076503737

SN - 1078-0432

VL - 25

SP - 7272

EP - 7274

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 24

ER -

Mogamulizumab forecast: Clearer patients, with a slight chance of immune mayhem

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this